BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 24952240)

  • 1. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
    Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
    J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.
    Pedrosa JA; Masterson TA; Rice KR; Bihrle R; Beck SD; Foster RS
    J Urol; 2014 Jun; 191(6):1777-82. PubMed ID: 24518787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Somatic-type" malignancies arising from testicular germ cell tumors: a clinicopathologic study of 124 cases with emphasis on glandular tumors supporting frequent yolk sac tumor origin.
    Magers MJ; Kao CS; Cole CD; Rice KR; Foster RS; Einhorn LH; Ulbright TM
    Am J Surg Pathol; 2014 Oct; 38(10):1396-409. PubMed ID: 24921638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival analysis of pure seminoma at post-chemotherapy retroperitoneal lymph node dissection.
    Rice KR; Beck SD; Bihrle R; Cary KC; Einhorn LH; Foster RS
    J Urol; 2014 Nov; 192(5):1397-402. PubMed ID: 24813309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical analysis of management of pediatric testicular germ cell tumors.
    Ye YL; Sun XZ; Zheng FF; Bian J; Huang YP; Zhang XQ; Li ZX; Nie Y; Qin ZK; Dai YP
    Urology; 2012 Apr; 79(4):892-7. PubMed ID: 22305424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ cell tumor associated primitive neuroectodermal tumors.
    Ganjoo KN; Foster RS; Michael H; Donohue JP; Einhorn LH
    J Urol; 2001 May; 165(5):1514-6. PubMed ID: 11342908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of stage I nonseminomatous testicular germ cell tumors.
    Pectasides D; Farmakis D; Pectasides M
    Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.
    Fedyanin M; Tryakin A; Bulanov A; Fainshtein I; Zakharova T; Matveev V; Garin A; Tjulandin S
    Urol Oncol; 2014 Jan; 32(1):32.e27-33. PubMed ID: 23628310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
    Divrik RT; Akdoğan B; Ozen H; Zorlu F
    J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of clinical-pathologic variables, staging and prognostic groups, and therapeutic results of 106 germ-cell testicular tumors.
    Bonet AS; Muñoz-Delgado EG; Vico FJ; Ruiz JC; Chapado MS
    Arch Esp Urol; 2011 Dec; 64(10):972-80. PubMed ID: 22228895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.
    Cost NG; Lubahn JD; Adibi M; Romman A; Wickiser JE; Raj GV; Sagalowsky AI; Margulis V
    J Urol; 2014 May; 191(5 Suppl):1485-90. PubMed ID: 24679874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teratoma with somatic-type malignant components in germ cell tumors of the testis: a clinicopathologic analysis of 40 cases with outcome correlation.
    Colecchia M; Necchi A; Paolini B; Nicolai N; Salvioni R
    Int J Surg Pathol; 2011 Jun; 19(3):321-7. PubMed ID: 21134986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. During twenty years of Cisplatin-based therapy the face of nonseminomatous testicular germ cell tumors is still changing: an evaluation of presentation, management, predictive factors and survival.
    Heinzelbecker J; Katzmarzik M; Weiss C; Trojan L; Haecker A
    Int Braz J Urol; 2013; 39(1):10-21. PubMed ID: 23489512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience.
    Scheckel CJ; Kosiorek HE; Butterfield R; Ho TH; Hilal T
    Oncol Res Treat; 2019; 42(3):95-100. PubMed ID: 30820020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.